• News
  • SAN DIEGO
  • Technology

Cytori receives notice of intent to exercise Option 1 of BARDA contract

San Diego's Cytori Therapeutics (Nasdaq: CYTX) received a preliminary written notice of intent to exercise Option 1 of its contract with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services.

Cytori was awarded a contract with BARDA worth up to $106 million in September 2012 for the development of Cytori Cell Therapy for thermal burns combined with radiation injury. On June 10, Cytori presented data generated during the base period of the contract at an in-process review (IPR) meeting, and the panel of representatives at the meeting determined that Cytori has accomplished the goals of the base period to the government’s satisfaction. These goals involved preclinical studies, preliminary design and development of Cytori’s next generation Celution System, and an assessment of Cytori’s technology in tissue samples from burn patients.

Based on this notification, Cytori and BARDA are in negotiations on the specifics for the additions to the statement of work to be executed in the Option 1 period, which will extend the contract to September 2016. It is anticipated that this process will take several weeks. Cytori will announce the contract details as soon as completed.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Cytori Therapeutics

Company Website

3020 Callan Road
San Diego, CA 92121